Boehringer In­gel­heim to con­struct a $300M+ fa­cil­i­ty at its HQ

Boehringer In­gel­heim plans to make a ma­jor in­vest­ment in­to man­u­fac­tur­ing chem­i­cals and ac­tive phar­ma­ceu­ti­cal in­gre­di­ents close to home.

The Ger­man phar­ma on Tues­day broke ground on what it is dub­bing the “Chem­i­cal In­no­va­tion Plant” lo­cat­ed at its head­quar­ters in In­gel­heim, Ger­many. Boehringer is in­vest­ing €285 mil­lion ($313.4 mil­lion) in­to the plant, which will pro­duce APIs in ad­di­tion to drugs that are in­tend­ed to be used in clin­i­cal tri­als. The cen­ter will aim to ad­vance new drug can­di­dates from its pipeline in­to the tri­al space.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER